One Year Following Single Administration, UniQure's Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX LevelsBenzinga • 06/22/21
UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve AcquisitionBenzinga • 06/22/21
uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)GlobeNewsWire • 06/22/21
uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory UpdateGlobeNewsWire • 06/22/21
uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 06/16/21
Alliance Data, Cimarex Energy, Myriad Genetics, Nestle and More Tuesday Afternoon Analyst Research Calls24/7 Wall Street • 06/15/21
UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in JuneGlobeNewsWire • 06/02/21
uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's DiseaseGlobeNewsWire • 05/27/21
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 VectorGlobeNewsWire • 05/13/21
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/10/21
CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovecPRNewsWire • 05/06/21
uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual MeetingGlobeNewsWire • 04/28/21
Strength Seen in uniQure (QURE): Can Its 8.3% Jump Turn into More Strength?Zacks Investment Research • 04/27/21
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving TodayBenzinga • 04/26/21
UniQure stock is up after FDA lifts clinical hold on experimental gene therapyMarket Watch • 04/26/21
Uniqure Stock Pops After FDA Says It Can Resume Gene Therapy TestsInvestors Business Daily • 04/26/21
UniQure's Stock Is Trading Higher As FDA Lifts Clinical Hold On Its Hemophilia B Gene Therapy ProgramBenzinga • 04/26/21
uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy ProgramGlobeNewsWire • 04/26/21